On September 18th, 2020, the Federal Service for Surveillance in Healthcare (Roszdravnadzor) adopted a new Order approving the criteria for blocking the websites with the content infringing the healthcare regulations.
The document establishes criteria for identifying and blocking websites that illegally sale or distribute content that forms a positive image of persons engaged in prohibited retail trade of medicines.
The key criteria for blocking a website are the following:
Right holders and the General Prosecutor are entitled to file a claim in court. Moreover, Roszdravnadzor is also entitled to make decisions on website blockage independently.
Upon the court’s or Roszdravnadzor’s decision on the website blocking, telecom operators and a hosting provider obtain a notification on the obligation to restrict access to the website with the infringing content. The telecom operator is obliged to immediately restrict access to the website. If the owner of the website deletes the infringing content within 24 hours, the access to the website is restored. Otherwise, the website remains blocked, unless there is a further specific court decision on its unblocking.
As for September 28th, 2020, 42 websites illegally selling medicines have been blocked based on the Order.
Summarizing the above, we would like to emphasize the following:
The new mechanism can be useful for ensuring protection of the right holders in the life science industry who face counterfeit sales.
Pharmaceutical companies, online retailers and online platforms should be more careful with their content related to life sciences industry.
Marketplaces and e-commerce retailers should specify requirements for the content to pharmaceutical sector in order to avoid their websites’ blockage due to the placement of the infringing content.
We hope that the information provided herein will be useful for you. If you or any of your colleagues would like to receive our newsletters via e-mail, please fill in the 'Subscribe' form at the bottom of the page.
Practice: Healthcare and Pharmaceutical
Note: Please be aware that all information provided in this letter was taken from open sources. Neither ALRUD Law Firm, nor the author of this letter bear any liability for consequences of any decisions made in reliance upon this information.